Delving into the Latest Updates on XSTEM with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

XSTEM-OA, XSTEM-VLU

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesCardiovascular DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Varicose UlcerOsteoarthritisOsteoarthritis, Knee+ [1]

Inactive Indication-

Originator Organization

Xintela AB

Active Organization

Xindu Pty Ltd

Xintela AB

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-VLU when administered as a single topical dose to patients with difficult-to-heal venous leg ulcers. The study is randomised and the patients will receive either XSTEM-VLU or vehicle as add on to standard wound care.
The patients will be followed weekly for 10 weeks after treatment. At 4 months after treatment, the patients will return to the clinic for an end-of-study visit.

Start Date26 Oct 2022

Sponsor / Collaborator

Xintela AB

[+1]

NCT05344157

/ Active, not recruitingPhase 1/2

A First-in-Human Open-Label Phase 1/2a Study to Evaluate Safety, Tolerability and Efficacy of a Single Intra-Articular Injection of Allogeneic Mesenchymal Stem Cells Selected for Integrin α10β1 (XSTEM-OA) in Adult Patients With Symptomatic Knee Osteoarthritis

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-OA when administered as a single intra-articular injection to patients with symptomatic knee osteoarthritis. The study is divided into two parts; a dose escalation (Part A) and an optional dose expansion part (Part: B). Three dose levels are planned to be evaluated in Part A and selected dose level(s) may be further expanded in Part B.

Start Date22 Jun 2022

Sponsor / Collaborator

Xindu Pty Ltd

[+1]

100 Clinical Results associated with XSTEM

Login to view more data

100 Translational Medicine associated with XSTEM

Login to view more data

100 Patents (Medical) associated with XSTEM

Login to view more data

100 Deals associated with XSTEM

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Varicose Ulcer	Phase 2	Sweden	Xintela AB	26 Oct 2022
Osteoarthritis	Phase 2	Australia	Xintela AB	22 Jun 2022
Osteoarthritis, Knee	Phase 2	Australia	Xindu Pty Ltd	22 Jun 2022
Respiratory Distress Syndrome, Adult	Preclinical	Sweden	Xintela AB	08 Oct 2024